Combining STING Agonists with PARP Inhibitors Mounts an NK-Dependent Defense against Therapy-Resistant Breast Cancer. Gohari Z, Stojanovic L, Rassool FV. Cancer Res 2025;85:1747-1749.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Gohari Z, Stojanovic L, Rassool FV. Combining STING Agonists with PARP Inhibitors Mounts an NK-Dependent Defense against Therapy-Resistant Breast Cancer. Cancer Res 2025;85:1747-1749.
PMID: 40370063